aTYR PHARMA (ATYR) Preferred Stock Liabilities (2014 - 2015)
aTYR PHARMA's (ATYR) quarterly Preferred Stock Liabilities came in at $141.3 million in Q1 2015, up 47.77% quarter-over-quarter from $95.6 million in Q4 2014.
Powered by 
Analysis
aTYR PHARMA (ATYR) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends
aTYR PHARMA (ATYR) has reported Preferred Stock Liabilities for 2 consecutive years, with $141.3 million the latest figure, recorded in Q1 2015.
- For the quarter ending Q1 2015, Preferred Stock Liabilities changed N/A year-over-year to $141.3 million; the trailing twelve-month figure through Mar 2015 stood at $141.3 million (changed N/A YoY), and the FY2014 full-year result was $95.6 million, up 2.63% from the prior year.
- Preferred Stock Liabilities advanced to $141.3 million in Q1 2015 per ATYR's latest filing, from $95.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $141.3 million in Q1 2015 and bottomed at $95.6 million in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | - |